Date: 2013-05-07
Type of information: R&D agreement
Compound: epicutaneous immunotherapy (EPIT®)
Company: DBV Technologies (France) Mount Sinai Hospital (USA)
Therapeutic area: Allergic diseases
Type agreement: R&D
clinical research
Action mechanism:
Disease: food allergy
Details: DBV Technologies and Mount Sinai Hospital have announced a partnership with the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai Hospital (New York) for research related to the mechanism by which epicutaneous immunotherapy (EPIT®) using Viaskin® leads to immune tolerance to food antigens. Drs. Cecilia Berin and Hugh Sampson will be principal investigators for the collaborative research. Dr. Sampson is also director of the Jaffe Food Allergy Institute, whose mission is to expand and improve basic science and clinical research, comprehensive patient care, and educational efforts in the field of food allergy.
This research program will be conducted over an 18-month period. The study objectives are focused on the efficacy of EPIT in food induced gastro-intestinal allergies. A first study will be focused on the EPIT® method as a treatment of food-induced anaphylaxis in mice, compared to oral immunotherapy (OIT). A second study will address the mechanism of tolerance induction, particularly the importance of the skin immune milieu and mechanism of regulatory T cells induction in the development of tolerance.
Financial terms:
Latest news:
